Mahe G, Aboyans V, Cosson E, Mohammedi K, Sarlon-Bartoli G, Laneelle D
Cardiovasc Diabetol. 2024; 23(1):220.
PMID: 38926722
PMC: 11210102.
DOI: 10.1186/s12933-024-02325-9.
Wanner C, Iliev H, Duarte N, Schueler E, Soares A, Thanam V
Adv Ther. 2024; 41(7):2826-2844.
PMID: 38771475
PMC: 11213770.
DOI: 10.1007/s12325-024-02879-w.
Htoo P, Tesfaye H, Schneeweiss S, Wexler D, Everett B, Glynn R
Diabetologia. 2024; 67(7):1328-1342.
PMID: 38509341
DOI: 10.1007/s00125-024-06126-3.
Cecchini A, Biscetti F, Manzato M, Sasso L, Rando M, Nicolazzi M
Int J Mol Sci. 2023; 24(22).
PMID: 38003290
PMC: 10671371.
DOI: 10.3390/ijms242216099.
Koutentakis M, Kucinski J, Swieczkowski D, Surma S, Filipiak K, Gasecka A
J Cardiovasc Dev Dis. 2023; 10(11).
PMID: 37998523
PMC: 10672595.
DOI: 10.3390/jcdd10110465.
Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours.
Guarnotta V, Emanuele F, Salzillo R, Bonsangue M, Amato C, Mineo M
Front Endocrinol (Lausanne). 2023; 14:1248985.
PMID: 37842314
PMC: 10569460.
DOI: 10.3389/fendo.2023.1248985.
The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study.
Goldman A, Fishman B, Twig G, Raschi E, Cukierman-Yaffe T, Moshkovits Y
Cardiovasc Diabetol. 2023; 22(1):16.
PMID: 36694178
PMC: 9875397.
DOI: 10.1186/s12933-023-01743-5.
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Lancet. 2022; 400(10365):1788-1801.
PMID: 36351458
PMC: 7613836.
DOI: 10.1016/S0140-6736(22)02074-8.
Physicians' Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors.
Jabbour S, Ibrahim N, Argyropoulos C
J Clin Med. 2022; 11(20).
PMID: 36294370
PMC: 9604628.
DOI: 10.3390/jcm11206051.
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice.
Skrabic R, Kumric M, Vrdoljak J, Rusic D, Skrabic I, Vilovic M
Biomedicines. 2022; 10(10).
PMID: 36289720
PMC: 9598622.
DOI: 10.3390/biomedicines10102458.
Safety of sodium-glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations.
Davidson J, Sukor N, Hew F, Mohamed M, Hussein Z
J Diabetes Investig. 2022; 14(2):167-182.
PMID: 36260389
PMC: 9889611.
DOI: 10.1111/jdi.13915.
Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study.
Lee Y, Dong Y, Yang W, Wu L, Lin J, Chang C
Front Pharmacol. 2022; 13:869804.
PMID: 36176438
PMC: 9513310.
DOI: 10.3389/fphar.2022.869804.
Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors.
Lin D, Yu A, Lo H, Lien C, Lee J, Chen W
Diabetologia. 2022; 65(12):2032-2043.
PMID: 35945333
DOI: 10.1007/s00125-022-05772-9.
Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.
Yau K, Dharia A, Alrowiyti I, Cherney D
Kidney Int Rep. 2022; 7(7):1463-1476.
PMID: 35812300
PMC: 9263228.
DOI: 10.1016/j.ekir.2022.04.094.
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.
Tuttle K, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske S
Diabetes Care. 2022; 45(6):1445-1452.
PMID: 35472672
PMC: 9210861.
DOI: 10.2337/dc21-2034.
Effects of Sodium-Glucose Cotransporter 2 on Amputation Events: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
See R, Teo Y, Teo Y, Syn N, Yip A, Leong S
Pharmacology. 2021; 107(3-4):123-130.
PMID: 34942623
PMC: 8985006.
DOI: 10.1159/000520903.
Management of Hyperglycemia in Older Adults with Type 2 Diabetes.
Gandhi G, Mooradian A
Drugs Aging. 2021; 39(1):39-58.
PMID: 34921341
DOI: 10.1007/s40266-021-00910-1.
Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials.
Staplin N, Roddick A, Emberson J, Reith C, Riding A, Wonnacott A
EClinicalMedicine. 2021; 41:101163.
PMID: 34765951
PMC: 8571171.
DOI: 10.1016/j.eclinm.2021.101163.
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Patorno E, Pawar A, Wexler D, Glynn R, Bessette L, Paik J
Diabetes Obes Metab. 2021; 24(3):442-454.
PMID: 34729891
PMC: 8939295.
DOI: 10.1111/dom.14593.
Comprehensive evaluation of cardiovascular efficacy and safety outcomes of SGLT2 inhibitors in high risk patients of cardiovascular disease: systematic review and meta-analysis.
Bhattarai M, Salih M, Regmi M, Al-Akchar M, Koester C, Ibrahim A
Cardiovasc Endocrinol Metab. 2021; 10(2):89-98.
PMID: 34113794
PMC: 8186520.
DOI: 10.1097/XCE.0000000000000229.
